OnCo

Vulvar cancer: lines of therapy

Cancer page →

4 standard-of-care settings across 4 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comers
Early / localised1
Locally advanced1
Second line1
Other settings1

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
All comersEarly (T1, <4 cm, unifocal)Radical local excision with 1 cm margin and sentinel lymph node biopsy (GROINSS-V); radiotherapy for sentinel micrometastases ≤2 mm, lymphadenectomy for macrometastases.91

Locally advanced

SubgroupSettingApproachProducts and trialsEvidence
All comersLocally advanced (T3 / fixed nodes)Definitive or neoadjuvant chemoradiation with weekly cisplatin (GOG 279: ~70% complete response), reserving exenterative surgery for residual disease.91

Second line

SubgroupSettingApproachProducts and trialsEvidence
All comersMetastatic or recurrentCarboplatin-paclitaxel ± bevacizumab (by cervical analogy); pembrolizumab for PD-L1 CPS ≥1, TMB-H or MSI-H; clinical trials.98

Other settings

SubgroupSettingApproachProducts and trialsEvidence
All comersNode-positive after surgeryAdjuvant radiotherapy to groins and pelvis (± concurrent cisplatin) for ≥2 nodes or extracapsular spread (AGO-CaRE-1 supports chemoradiation).91

Regimens in the library

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.